blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1776387

EP1776387 - ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM MAB CL1-R2 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.06.2011
Database last updated on 20.09.2024
Most recent event   Tooltip19.10.2012Lapse of the patent in a contracting state
New state(s): TR		published on 21.11.2012  [2012/47]
Applicant(s)For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75654 Paris Cedex 13 / FR
[2010/30]
Former [2007/17]For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101 rue de Tolbiac
75654 Paris Cedex 13 / FR
Inventor(s)01 / BENSUSSAN, Armand
16 rue Auguste Lançon
F-75013 Paris / FR
02 / BOUMSELL, Laurence
35, quai de Grenelle
F-75015 PARIS / FR
03 / LE BOUTEILLER, Philippe
4, rue Toulouse-Lautrec
F-31700 Blagnac / FR
 [2007/17]
Representative(s)Touati, Catherine
Cabinet Plasseraud
ATTENTION : ADDRESS INACTIVE - USE ASS-NR - CDR
Paris / FR
[N/P]
Former [2007/17]Touati, Catherine
Cabinet Plasseraud 52 rue de la Victoire
75440 Paris Cedex 09 / FR
Application number, filing date05789182.209.08.2005
[2007/17]
WO2005EP09231
Priority number, dateEP2004029201509.08.2004         Original published format: EP 04292015
[2007/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006015886
Date:16.02.2006
Language:EN
[2006/07]
Type: A1 Application with search report 
No.:EP1776387
Date:25.04.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 16.02.2006 takes the place of the publication of the European patent application.
[2007/17]
Type: B1 Patent specification 
No.:EP1776387
Date:28.07.2010
Language:EN
[2010/30]
Search report(s)International search report - published on:EP16.02.2006
ClassificationIPC:C07K16/28, A61K39/395, A61P35/00, A61P37/00, A61P31/00
[2007/17]
CPC:
C07K16/2803 (EP,US); C07K16/2836 (US); A61P15/00 (EP);
A61P19/02 (EP); A61P27/02 (EP); A61P29/00 (EP);
A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P7/00 (EP);
A61P9/00 (EP); A61P9/08 (EP); A61P9/10 (EP);
A61P9/12 (EP); C07K16/2896 (US); A61K2039/505 (US);
C07K2317/14 (US); C07K2317/75 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/17]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:ANGIOGENISCHE UND IMMUNOLOGISCHE VERWENDUNGEN VON ANTI-CD160 SPEZIFISCHEN STOFFEN, ERHÄLTLICH VOM MONOKLONALEN ANTIKÖPER CL1-R2[2007/17]
English:ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM MAB CL1-R2[2007/17]
French:APPLICATIONS ANGIOGENIQUES ET IMMUNOLOGIQUES DE COMPOSES SPECIFIQUES ANTI-CD160 POUVANT ETRE OBTENUS A PARTIR DE L'ANTICORPS MONOCLONAL CL1-R2[2010/10]
Former [2007/17]APPLICATIONS ANGIOGÉNIQUES ET IMMUNOLOGIQUES DE COMPOSÉS SPÉCIFIQUES ANTI-CD160 POUVANT ÊTRE OBTENUS À PARTIR DE L'ANTICORPS MONOCLONAL CL1-R2
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase20.02.2007National basic fee paid 
20.02.2007Designation fee(s) paid 
20.02.2007Examination fee paid 
Examination procedure29.05.2006Request for preliminary examination filed
International Preliminary Examining Authority: EP
20.02.2007Examination requested  [2007/17]
02.06.2009Despatch of a communication from the examining division (Time limit: M06)
17.11.2009Reply to a communication from the examining division
18.02.2010Communication of intention to grant the patent
09.06.2010Fee for grant paid
09.06.2010Fee for publishing/printing paid
Opposition(s)29.04.2011No opposition filed within time limit [2011/27]
Fees paidRenewal fee
13.08.2007Renewal fee patent year 03
04.09.2008Renewal fee patent year 04
31.08.2009Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.08.200804   M06   Fee paid on   04.09.2008
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY28.07.2010
CZ28.07.2010
EE28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
RO28.07.2010
SI28.07.2010
SK28.07.2010
TR28.07.2010
IE09.08.2010
LU09.08.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
HU29.01.2011
[2012/47]
Former [2012/44]CY28.07.2010
CZ28.07.2010
EE28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
RO28.07.2010
SI28.07.2010
SK28.07.2010
IE09.08.2010
LU09.08.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
HU29.01.2011
Former [2012/42]CY28.07.2010
CZ28.07.2010
EE28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
RO28.07.2010
SI28.07.2010
SK28.07.2010
IE09.08.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
HU29.01.2011
Former [2011/36]CY28.07.2010
CZ28.07.2010
EE28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
RO28.07.2010
SI28.07.2010
SK28.07.2010
IE09.08.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
Former [2011/29]CY28.07.2010
CZ28.07.2010
EE28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
RO28.07.2010
SI28.07.2010
SK28.07.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
Former [2011/23]CY28.07.2010
CZ28.07.2010
EE28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
SI28.07.2010
SK28.07.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
Former [2011/16]CY28.07.2010
FI28.07.2010
LT28.07.2010
LV28.07.2010
SI28.07.2010
MC31.08.2010
BG28.10.2010
GR29.10.2010
IS28.11.2010
PT29.11.2010
Former [2011/13]CY28.07.2010
FI28.07.2010
LT28.07.2010
SI28.07.2010
BG28.10.2010
IS28.11.2010
PT29.11.2010
Former [2011/12]FI28.07.2010
LT28.07.2010
SI28.07.2010
BG28.10.2010
PT29.11.2010
Former [2011/08]LT28.07.2010
Cited inInternational search[A]WO9821240  (DANA FARBER CANCER INST INC [US], et al) [A] 1-53 * the whole document *;
 [X]WO03018048  (ABTECH [FR], et al) [X] 1-53 * the whole document *;
 [X]  - LASO F J ET AL, "Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake.", ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH. OCT 1997, (199710), vol. 21, no. 7, ISSN 0145-6008, pages 1226 - 1231, XP009043061 [X] 52 * page 1228, column L, paragraph 2 * * page 1228, column L, paragraph 4 - page 1230, column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1097/00000374-199710000-00011
 [A]  - LE BOUTEILLER PHILIPPE ET AL, "Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20021224), vol. 99, no. 26, ISSN 0027-8424, pages 16963 - 16968, XP002315421 [A] 1-53 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.012681099
 [A]  - AGRAWAL S ET AL, "Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 FEB 1999, (19990201), vol. 162, no. 3, ISSN 0022-1767, pages 1223 - 1226, XP002315422 [A] 1-53 * the whole document *
 [T]  - BARAKONYI ALIZ ET AL, "Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 NOV 2004, (20041101), vol. 173, no. 9, ISSN 0022-1767, pages 5349 - 5354, XP002315423 [T] 1-53 * the whole document *
 [A]  - ANUMANTHAN A ET AL, "Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 1998, (19980915), vol. 161, no. 6, ISSN 0022-1767, pages 2780 - 2790, XP002315424 [A] 1-53 * the whole document *
 [A]  - NIKOLOVA MARIA ET AL, "BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.", INTERNATIONAL IMMUNOLOGY. MAY 2002, (200205), vol. 14, no. 5, ISSN 0953-8178, pages 445 - 451, XP002315425 [A] 1-53 * the whole document *

DOI:   http://dx.doi.org/10.1093/intimm/14.5.445
 [A]  - BD BIOSCIENCES, "Fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD160 monoclonal antibody", (20011019), pages 1 - 1, URL: http://www.bdbiosciences.com/external_files/pm/doc/tds/human/live/web_enabled/38484X_551888.pdf, (20050103), XP002315772 [A] 1-53 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.